The Global Health Observatory

Explore a world of health data

Short name:
IA2030 – IG 2.2 Provide access to all vaccines
Data type:
Count
Rationale:
Indicator selected for global monitoring for Immunization Agenda 2030 Impact Goal Indicator 2.2:

Introduction of new or underutilized vaccines in low- and middle-income countries. Global, regional, and country partners can use findings from this indicator to identify countries that are remaining to introduce WHO recommended vaccines in order to focus efforts to ensure equitable access to vaccines. The indicator will help to assess whether there are opportunities to support country vaccination introductions for new and underutilized vaccines. Further in-depth evaluation or root cause analysis could be considered to determine barriers to vaccine introduction for the countries that have not yet introduced WHO recommended vaccines.

Definition:
Number of introductions of new or under-utilized vaccines in low- and middle-income countries based on most recent World Bank income status classification at the time of reporting. Year of introduction is based on the year the vaccine was first reported, including cases where a vaccine was introduced and was suspended or not administered.
    Vaccines included in this indicator that are recommended by WHO for use in national immunization schedules in all countries: HepB birth dose, Hib, HPV, IPV2, MCV2, PCV, Rotavirus, Rubella, DTP booster (currently reporting the fourth dose regardless of what age it was administered), and COVID-19 (interim recommendation).
  • Only national introductions are included for the indicator reporting based on WHO recommendations
    • (https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/who-recommendations-for-routine-immunization---summary-tables)
  • Aligning with the Gavi application guidelines, each DTP booster dose is considered an introduction (e.g., two DTP booster vaccine introductions if country introduced two of the three boosters). It is considered an introduction if the vaccine was provided outside the WHO recommended age range (https://iris.who.int/bitstream/handle/10665/329882/9789241515610-eng.pdf?sequence=1&isAllowed=y).
    Vaccines included in this indicator that are recommended by WHO for use in national immunization schedules in countries in certain geographic region(s), in some high-risk populations, or in immunization programmes with certain characteristics: YF, JE, MenA, multivalent meningitis, HepA, influenza, varicella, mumps, malaria, typhoid, and dengue.
  • MenA vaccine indicator reporting only for countries in the meningitis belt of sub-Saharan Africa. Multivalent meningitis vaccine indicator reporting for countries not in the meningitis belt of sub-Saharan Africa.
  • As part of the indicator revision in spring 2024, reporting on Typhoid vaccine started in 2023 and only includes national introductions for now.
  • Data collection on dengue vaccine from 2024 onwards.

Target: At least 500 cumulative vaccine introductions in low- and middle-income countries between 2021 and 2030 (including current new or under-utilized vaccines as well as vaccines that will be recommended over the decade)

Associated terms:
Vaccine introduction: Addition of a vaccine to the national immunization schedule and officially reported by the country (excludes vaccines used only in the private sector that are not in national immunization schedule; immunization schedules that are used in at risk populations).
New or underutilized vaccines: Vaccines that have not yet been introduced into national immunization schedules in all countries where recommended by WHO.
Disaggregation:
Low- and middle-income countries among WHO Member States
Method of measurement
National immunization programme
M&E Framework:
Process
Method of estimation:
Step 1: Count the number of introductions of new or under-utilized vaccines in low- and middle-income countries among WHO Member States.
  • Only the low- and middle-income countries based on most recent World Bank income status classification at the time of annual reporting should be included.
    • Method of estimation of global and regional aggregates:
    Sum
    Preferred data sources:
    WHO/UNICEF Joint Reporting Form on Immunization (JRF)
    Unit of Measure:
    N/A
    Unit Multiplier:
    N/A
    Expected frequency of data dissemination:
    Annual
    Expected frequency of data collection:
    Annual (includes historical data updates; when data is missing or data is reported inconsistently, historical trends and coverage data reporting is reviewed to support introduction status)
    Contact person email:
    vpdata@who.int
    IMRID:
    7775
    Limitations:
    Vaccine may have been introduced earlier than reported but reporting is based on official data from the WHO Member States.
    Although countries report having introduced select vaccines in national immunization schedules, it does not mean children are vaccinated.
    Links:
    IA2030 Annex 1: Monitoring and Evaluation Framework || https://immunizationagenda2030.org/images/documents/IA2030_Annex_FrameworkForActionv04.pdf
    IA2030 Scorecard: IG 2.2 Provide access to all vaccines || https://scorecard.immunizationagenda2030.org/ig2.2
    WHO Immunization Data Portal: New and underutilized vaccine introduction || https://immunizationdata.who.int/pages/indicators-by-category/new_and_under_utilized_vaccines_introduction.html?ISO_3_CODE=&YEAR=
    If you have any feedback, you are welcome to write it here.
    If you need to access the old Global Health Observatory data, you can do it here. But before you leave, please provide us your feedback about our new data portal.